Skip to main content

Table 2 Full exclusion criteria

From: MDLSD: study protocol for a randomised, double-masked, placebo-controlled trial of repeated microdoses of LSD in healthy volunteers

  Exclusion criteria
Consent/communication Inability to speak or read English
Physiological health
 Diagnosis Unstable medical or neurologic condition as assessed by the study physician
 Lab work Significant renal or hepatic impairment
 Vital signs Cardiovascular conditions including abnormal heart rate seen by ECG
Resting blood pressure not exceeding 160 mmHg systolic and 90 mmHg diastolic
Body weight between 50 and 120 kg
 Medical history Contraindications for MRI scanning
Mental health
 Diagnosis Lifetime history of major depressive disorder, schizophrenia or other psychotic disorders, or bipolar I or II disorder as assessed by the Mini International Neuropsychiatric Interview (MINI)
Current diagnosis of PTSD, anxiety and panic disorders, OCD, dysthymic disorder, anorexia, and bulimia as assessed by the Standard MINI
 Current risk Elevated of suicide as determined by study psychiatrist using the Columbia-Suicide Severity Rating Scale (C-SSRS)
Elevated risk of developing psychosis as determined by the study psychiatrist using the Comprehensive Assessment of At Risk Mental States (CAARMS)
 Family diagnosis First-degree relatives diagnosed with schizophrenia or other primary psychotic disorder, or bipolar I or II disorder
 Medication Current use of any prescribed psychotropic medication
 Substance use Substance use disorder in the previous 3 months as assessed with a New Zealand modified version of the NM-ASSIST
Failed breathalyser and/or multipanel drug urine tests at screening with one follow up in trial
Use of serotonergic psychedelic drugs in the last year
Lifetime history of psychedelic microdosing